Abstract
Purpose
Mina53, whose expression is directly induced by c-Myc, is overexpressed in various cancers and plays an important role in cell growth. To clarify the involvement of Mina53 in lung cancers, we investigated its expression in human lung cancer tissues as well as in various lung cancer cell lines.
Methods
Mina53 expression was determined by real-time RT-PCR, western blotting, and immunohistochemistry using lung cancer cell lines, normal human bronchial epithelial cells, and lung cancer tissues. Biological effects of Mina53 were evaluated by soft agar colony formation assay and tumorigenicity in nude mice using Mina53-transfected NIH/3T3 cells. cDNA microarray analysis was performed to determine the gene alteration by Mina53 and confirmation was made using real-time RT-PCR with mina53 expression plasmid or mina53 shRNA-transfected NIH/3T3 cells.
Results
We observed that 62% of patients evidenced overexpression of Mina53 from the early clinical stages of lung cancer. Differences according to gender, smoking status, or histologic type were not statistically significant. Forced expression of Mina53 in NIH/3T3 cells induced cell transformation, and mina53-transfected NIH/3T3 clones produced tumors in nude mice, demonstrating that Mina53 has oncogenic potential. cDNA microarray revealed that 254 genes had altered expression in a mina53-transfected NIH/3T3 clone. Mina53 regulates several genes related to cell adhesion and metabolism, which have also been reported to be regulated by c-Myc. Genes regulated by Mina53, but not by c-Myc included cytokine/growth factor related genes such as EGFR, IL-6, and HGF.
Conclusion
Our results suggest that Mina53 plays an important role in carcinogenesis and may be a target for cancer prevention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- HBE cells:
-
Human bronchial epithelial cells
- Mina53:
-
Myc-induced nuclear antigen with a molecular mass of 53 kDa
- IL-6:
-
Interleukin-6
- HGF:
-
Hepatocyte growth factor
- EGFR:
-
Epidermal growth factor receptor
- Cox-2:
-
Cyclooxygenase-2
References
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804
“Cancer Statistics in Japan” Editorial Board (2005) Number of deaths and proportional mortality rates from malignant neoplasms by site in Japan. In: Nomura K, Sobue T, Nakatani H, et al. (eds) Cancer Statistics in Japan, 2005, Foundation for Promotion of Cancer Research, Tokyo, pp 36–39
Choi JK, Lee SG, Lee JY, Nam HY, Lee WK, Lee KH, Kim HJ, Lim Y (2005) Silica induces human cyclooxygenase-2 gene expression through the NF-kappa B signaling pathway. J Environ Pathol Toxicol Oncol 24:163–174
Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F (2006) The c-Myc target gene network. Semin Cancer Biol 16:253–264
Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199–207
Fukahori S, Yano H, Tsuneoka M, Tanaka Y, Yagi M, Kuwano M, Tajiri T, Taguchi T, Tsuneyoshi M, Kojiro M (2007) Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. J Pediatr Surg 42:1831–1840
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846–3856
Herbst RS, Bunn PA Jr (2003) Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9:5813–5824
Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002) The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21:3414–3421
Ikari T, Hiraki A, Seki K, Sugiura T, Matsumoto K, Shirasuna K (2003) Involvement of hepatocyte growth factor in branching morphogenesis of murine salivary gland. Dev Dyn 228:173–184
Ishizaki H, Yano H, Tsuneoka M, Ogasawara S, Akiba J, Nishida N, Kojiro S, Fukahori S, Moriya F, Matsuoka K, Kojiro M (2007) Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol Int 57:672–680
Jenkins BJ, Roberts AW, Greenhill CJ, Najdovska M, Lundgren-May T, Robb L, Grail D, Ernst M (2007) Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109:2380–2388
Knoepfler PS (2007) Myc goes global: new tricks for an old oncogene. Cancer Res 67:5061–5063
Knott AW, Erwin CR, Profitt SA, Juno RJ, Warner BW (2003) Localization of post resection EGF receptor expression using laser capture microdissection. J Pediatr Surg 38:440–445
Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M, Tanaka S (2001) Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg 7:197–203
Land H, Parada LF, Weinberg RA (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596–602
Lüscher B (2001) Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 277:1–14
Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M (2007) c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 98:1006–1013
Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18:3004–3016
Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669–672
Shiraishi M, Noguchi M, Shimosato Y, Sekiya T (1989) Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 49:6474–6479
Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350:379–392
Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS (2007) Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci USA 104:18514–18519
Sueoka-Aragane N, Imai K, Komiya K, Sato A, Tomimasu R, Hisatomi T, Sakuragi T, Mitsuoka M, Hayashi S, Nakachi K, Sueoka E (2008) Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci 99:1180–1187
Sunaga S, Maki K, Komagata Y, Ikuta K, Miyazaki JI (1997) Efficient removal of loxP-flanked DNA sequences in a gene-targeted locus by transient expression of Cre recombinase in fertilized eggs. Mol Reprod Dev 46:109–113
Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II (2006) Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107:2637–2646
Teye K, Tsuneoka M, Arima N, Koda Y, Nakamura Y, Ueta Y, Shirouzu K, Kimura H (2004) Increased expression of a Myc target gene Mina53 in human colon cancer. Am J Pathol 164:205–216
Teye K, Arima N, Nakamura Y, Sakamoto K, Sueoka E, Kimura H, Tsuneoka M (2007) Expression of Myc target gene mina53 in subtypes of human lymphoma. Oncol Rep 18:841–848
Tichelaar JW, Zhang Y, leRiche JC, Biddinger PW, Lam S, Anderson MW (2005) Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer 5:155
Tsao MS, Liu N, Chen JR, Pappas J, Ho J, To C, Viallet J, Park M, Zhu H (1998) Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20:1–16
Tsuneoka M, Koda Y, Soejima M, Teye K, Kimura H (2002) A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem 277:35450–35459
Tsuneoka M, Fujita H, Arima N, Teye K, Okamura T, Inutsuka H, Koda Y, Shirouzu K, Kimura H (2004) Mina53 as a potential prognostic factor for esophageal squamous cell carcinoma. Clin Cancer Res 10:7347–7356
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893–898
Yeh HH, Lai WW, Chen HH, Liu HS, Su WC (2006) Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25:4300–4309
Yokota J, Kohno T (2004) Molecular footprints of human lung cancer progression. Cancer Sci 95:197–204
Zhang Y, Lu Y, Yuan BZ, Castranova V, Shi X, Stauffer JL, Demers LM, Chen F (2005) The human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer. Oncogene 24:4873–4882
Acknowledgments
This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Smoking Research Foundation.
Conflict of interest statement
None declared.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Komiya, K., Sueoka-Aragane, N., Sato, A. et al. Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J Cancer Res Clin Oncol 136, 465–473 (2010). https://doi.org/10.1007/s00432-009-0679-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0679-0